A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

Sixty naive patients with HIV and confirmed hepatitis C who are co-enrolled in another AACTG antiretroviral study that involves the testing of HAART (Highly Active Antiretroviral Therapy) are entered on this prospective study. Patients who are defined as naive have never received specific, active antiretroviral agents that sustain viral suppression below the limit of detection (500 copies/ml) or have received those agents for only a very limited time. HAART is defined as therapy which is likely to result in HIV-1 RNA plasma levels less than 500 copies/ml for at least 16 weeks. Plasma is col...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients may be eligible for this study if they:
• • Are HIV-positive and have Hepatitis C.
• • Have an HIV blood level of at least 2,500 copies/ml 30 days before study entry.
• • Are co-enrolled in an active adult AIDS clinical trial using anti-HIV treatment.
• • Are at least 13 years of age (parent or guardian consent required if under 18).
• • Exclusion Criteria
• Patients will not be eligible for this study if they:
• • Have liver disease.
• • Have cancer requiring chemotherapy.
• • Have Hepatitis B.
• • Abuse alcohol and/or drugs.
• • Have received certain antiretroviral (anti-HIV) drugs in the past.

Trial Officials